[{"address1": "12278 Scripps Summit Drive", "city": "San Diego", "state": "CA", "zip": "92131", "country": "United States", "phone": "858 875 1800", "website": "https://www.fatetherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.", "fullTimeEmployees": 181, "companyOfficers": [{"maxAge": 1, "name": "Dr. Bahram  Valamehr M.B.A., Ph.D.", "age": 48, "title": "President, CEO & Director", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 676600, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cindy R. Tahl J.D.", "age": 52, "title": "Chief Legal & Compliance Officer and Corporate Secretary", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 644600, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kamal  Adawi M.S., MBA", "age": 46, "title": "Chief Financial Officer", "yearBorn": 1979, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jessica  Francis", "title": "Vice President Of Human Resources & Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Henry", "age": 61, "title": "Senior Vice President of Clinical Operations", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tunde  Babalola Ph.D.", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yu  Cai J.D., Ph.D.", "title": "Head of Intellectual Property & Assistant General Counsel", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kate  Duvall", "title": "Corporate Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 3, "compensationRisk": 6, "shareHolderRightsRisk": 10, "overallRisk": 7, "governanceEpochDate": 1768176000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.25, "open": 1.25, "dayLow": 1.2, "dayHigh": 1.2799, "regularMarketPreviousClose": 1.25, "regularMarketOpen": 1.25, "regularMarketDayLow": 1.2, "regularMarketDayHigh": 1.2799, "payoutRatio": 0.0, "beta": 2.231, "forwardPE": -1.0461066, "volume": 1359828, "regularMarketVolume": 1359828, "averageVolume": 1700031, "averageVolume10days": 1998410, "averageDailyVolume10Day": 1998410, "bid": 1.19, "ask": 1.24, "bidSize": 15, "askSize": 15, "marketCap": 139576272, "fiftyTwoWeekLow": 0.66, "fiftyTwoWeekHigh": 1.94, "allTimeHigh": 121.16, "allTimeLow": 0.66, "priceToSalesTrailing12Months": 19.556715, "fiftyDayAverage": 1.059, "twoHundredDayAverage": 1.1506, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3401269, "profitMargins": 0.0, "floatShares": 100798291, "sharesOutstanding": 115352289, "sharesShort": 10065114, "sharesShortPriorMonth": 8184722, "sharesShortPreviousMonthDate": 1764288000, "dateShortInterest": 1767139200, "sharesPercentSharesOut": 0.087299995, "heldPercentInsiders": 0.01904, "heldPercentInstitutions": 0.79296994, "shortRatio": 7.4, "shortPercentOfFloat": 0.0995, "impliedSharesOutstanding": 115352289, "bookValue": 2.029, "priceToBook": 0.5963529, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -156094000, "trailingEps": -1.33, "forwardEps": -1.15667, "enterpriseToRevenue": 0.477, "enterpriseToEbitda": -0.023, "52WeekChange": -0.08759123, "SandP52WeekChange": 0.14987159, "quoteType": "EQUITY", "currentPrice": 1.21, "targetHighPrice": 8.0, "targetLowPrice": 2.0, "targetMeanPrice": 4.94444, "targetMedianPrice": 5.0, "recommendationKey": "none", "numberOfAnalystOpinions": 9, "totalCash": 215423008, "totalCashPerShare": 1.868, "ebitda": -145343008, "totalDebt": 79245000, "quickRatio": 7.737, "currentRatio": 7.871, "totalRevenue": 7137000, "debtToEquity": 33.856, "revenuePerShare": 0.06, "returnOnAssets": -0.23847, "returnOnEquity": -0.52346003, "grossProfits": -92406000, "freeCashflow": -61314248, "operatingCashflow": -110569000, "revenueGrowth": -0.434, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -19.95118, "financialCurrency": "USD", "symbol": "FATE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1380634200000, "postMarketChangePercent": 0.0, "postMarketPrice": 1.21, "postMarketChange": 0.0, "regularMarketChange": -0.04, "regularMarketDayRange": "1.2 - 1.2799", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 1700031, "epsTrailingTwelveMonths": -1.33, "epsForward": -1.15667, "epsCurrentYear": -1.14889, "priceEpsCurrentYear": -1.0531905, "fiftyDayAverageChange": 0.15100002, "fiftyDayAverageChangePercent": 0.14258736, "twoHundredDayAverageChange": 0.05940008, "twoHundredDayAverageChangePercent": 0.05162531, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "shortName": "Fate Therapeutics, Inc.", "longName": "Fate Therapeutics, Inc.", "fiftyTwoWeekLowChange": 0.55, "fiftyTwoWeekLowChangePercent": 0.8333333, "fiftyTwoWeekRange": "0.66 - 1.94", "fiftyTwoWeekHighChange": -0.73, "fiftyTwoWeekHighChangePercent": -0.37628865, "fiftyTwoWeekChangePercent": -8.759123, "earningsTimestamp": 1763040600, "earningsTimestampStart": 1763040600, "earningsTimestampEnd": 1763040600, "earningsCallTimestampStart": 1715288400, "earningsCallTimestampEnd": 1715288400, "isEarningsDateEstimate": false, "corporateActions": [], "postMarketTime": 1769206478, "regularMarketTime": 1769202002, "exchange": "NGM", "messageBoardId": "finmb_39268712", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -3.2, "regularMarketPrice": 1.21, "marketState": "CLOSED", "cryptoTradeable": false, "displayName": "Fate Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-01-24"}]